Ankylosing Spondylitis Market By Drug Class/Treatment Type (TNF Inhibitors, IL-17 Inhibitors, NSAIDs, JAK Inhibitors, Conventional DMARDs & Other Treatments); By Route of Administration (Parenteral / Injectable Therapies, Oral Therapies); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Ankylosing Spondylitis Market Expands With Targeted Therapies – (Updated On: 26-Sep-2026)

The Global Ankylosing Spondylitis Market was valued at USD 6.10 billion in 2025 and is projected to reach USD 9.98 billion by 2032, expanding at a CAGR of 7.25% during 2026–2032, according to Strategic Market Research.

 

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the axial skeleton, especially the spine and sacroiliac joints. Progressive inflammation can lead to stiffness, reduced mobility, and structural spinal changes, creating long-term demand for pharmacological therapies and disease-management solutions. Ankylosing spondylitis affects approximately 0.2% to 0.5% of the U.S. population and around 0.1% to 1.4% of the global population, creating a substantial patient pool requiring continuous therapeutic management.

 

The treatment landscape for ankylosing spondylitis has shifted from symptom management toward targeted immune therapies. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the initial treatment approach and are used by approximately 55% to 78% of diagnosed patients depending on disease severity and clinical guidelines. Patients with inadequate response often progress to advanced biologic therapies, including tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors, which represent major revenue contributors within the market. Emerging adoption of Janus kinase (JAK) inhibitors, including oral targeted therapies, is expanding treatment options, with approximately 15,000 to 25,000 active AS patients in the U.S. estimated to be using JAK inhibitor therapies.

 

UCB is a key technology-focused participant in the Ankylosing Spondylitis Market through BIMZELX (bimekizumab), a humanized monoclonal antibody that uses dual-cytokine inhibition technology to selectively inhibit both IL-17A and IL-17F, two cytokines involved in inflammatory processes.

 

Overall market development is shifting toward earlier diagnosis, targeted biologics, oral small-molecule therapies, personalized treatment selection, and technologies capable of controlling specific inflammatory pathways.

 

Established Biologics and Oral Therapies Set Different Growth Paths

By Drug Class / Treatment Type

Leading Subsegment – TNF Inhibitors

TNF Inhibitors dominate the drug-class segment, accounting for a 38% share with USD 2.318 billion in 2025 revenue, and are projected to expand at a CAGR of 5.30% during 2026–2032. TNF inhibitors are biologic therapies used in ankylosing spondylitis treatment to reduce inflammation by blocking tumor necrosis factor-alpha (TNF-α), a key inflammatory protein involved in spinal and joint damage. These therapies help alleviate pain, stiffness, and disease activity in patients who do not achieve adequate control with NSAIDs. Leading medications include adalimumab, etanercept, infliximab, golimumab, and certolizumab pegol, supporting their continued adoption in the ankylosing spondylitis therapeutics market.

Fastest-Growing Subsegment – JAK Inhibitors

JAK Inhibitors represent 13% of the market, equivalent to USD 0.793 billion in 2025 revenue, and are projected to record the fastest CAGR of 13.20% during 2026–2032. Their growth is supported by the transition toward targeted oral therapies that inhibit intracellular Janus kinase signaling rather than extracellular inflammatory cytokines. The segment provides an important alternative to injectable biologics for appropriate patients. The 2025 British Society for Rheumatology guideline recognizes JAK inhibitors alongside TNF and IL-17 inhibitors for active axial spondyloarthritis inadequately controlled by conventional treatment.

 

By Route of Administration

Leading Subsegment – Parenteral / Injectable

Parenteral and injectable therapies represent the leading treatment category in the Ankylosing Spondylitis Market, accounting for a 68% share equivalent to USD 4.148 billion in 2025 revenue. These therapies are primarily driven by the increasing adoption of biologic agents, including TNF inhibitors and IL-17 inhibitors, for patients with moderate-to-severe AS who require targeted control of chronic inflammation. Injectable biologics enable systemic disease management by directly modulating immune pathways, while localized corticosteroid injections provide short-term relief for peripheral joint and sacroiliac inflammation. The segment is projected to expand at a CAGR of 6.70% during 2026–2032.

Fastest-Growing Subsegment – Oral

Oral therapies represented a 32% share of the Ankylosing Spondylitis Market, accounting for USD 1.952 billion in 2025 revenue, and are expected to expand at the highest CAGR of 8.40% during 2026–2032. Growth is supported by the continued use of oral NSAIDs as first-line therapy, increasing adoption of oral targeted synthetic DMARDs, and the convenience of non-injectable treatment options for long-term disease management.

 

By Distribution Channel

Leading Subsegment – Hospital Pharmacies

Hospital Pharmacies dominate the Ankylosing Spondylitis Market by distribution channel, accounting for a 48% share, equivalent to USD 2.928 billion in 2025 revenue, and are expected to grow at a CAGR of 6.40% during 2026–2032. Hospital pharmacies support AS treatment by ensuring the availability, storage, and controlled dispensing of advanced therapies, including biologics and targeted medicines. They manage specialty drug procurement, maintain cold-chain requirements, support treatment continuity, and assist healthcare providers in optimizing long-term medication management for patients.

Fastest-Growing Subsegment – Online Pharmacies

Online Pharmacies account for an 18% share, generating USD 1.098 billion in 2025 revenue, and are expected to witness the fastest CAGR of 10.10% during 2026–2032. These platforms support Ankylosing Spondylitis (AS) treatment by providing convenient access to biologics, oral therapies, and specialty medications while addressing challenges related to drug storage, insurance coordination, and continuous therapy management. Online pharmacies improve medication accessibility for AS patients by enabling home delivery, cold-chain handling for temperature-sensitive biologics, refill support, and assistance with reimbursement processes, helping maintain treatment adherence.

 

By Geography

Leading Subsegment – North America

North America represents the largest regional segment of the Ankylosing Spondylitis Market, accounting for a 42% share with USD 2.562 billion in 2025 revenue and is expected to grow at a CAGR of 6.20% during 2026–2032. The regional market growth is supported by increasing disease awareness, improved diagnosis of axial spondyloarthritis conditions, rising adoption of biologic therapies, and advancements in targeted treatment approaches. Expanding access to rheumatology care and growing healthcare expenditure continue to strengthen AS management across North America.

Fastest-Growing Subsegment – Asia-Pacific

Asia-Pacific accounts for a 21% share of the Ankylosing Spondylitis Market, valued at USD 1.281 billion in 2025 revenue, and is expected to expand at the highest regional CAGR of 9.60% during 2026–2032. The region is witnessing increasing demand for early diagnosis, biologic therapies, and advanced disease management approaches due to rising awareness of inflammatory spinal disorders, improving rheumatology infrastructure, and growing access to targeted treatments across emerging healthcare markets.

 

Competition Intensifies Across JAK and IL-17 Treatment Platforms

AbbVie – JAK Inhibition and Established TNF Therapy

AbbVie has a strong position in AS treatment through RINVOQ (upadacitinib), an oral selective and reversible JAK inhibitor, alongside its established TNF-inhibitor franchise. RINVOQ is particularly relevant to the market's transition toward oral targeted therapy because it inhibits intracellular JAK-dependent inflammatory signaling rather than requiring biologic injection. In the Phase 3 SELECT-AXIS 2 study involving biologic-DMARD inadequate responders, 45% of patients receiving RINVOQ achieved ASAS40 at Week 14 compared with 18% receiving placebo. Patients also demonstrated improvements in back pain, physical function, and MRI-measured spinal inflammation.

Commercially, AbbVie reported USD 8.304 billion in global RINVOQ net revenue in 2025, up 39.1% year over year, across all of the product's indications. AbbVie's overall immunology portfolio generated USD 30.406 billion during 2025. These figures demonstrate the commercial scale supporting continued penetration and development of its targeted immunology platform, although they are not AS-specific sales.

 

Novartis – Established IL-17A Inhibition

Novartis competes through COSENTYX (secukinumab), a monoclonal antibody targeting interleukin-17A (IL-17A). The technology directly inhibits a cytokine involved in the inflammatory pathways underlying ankylosing spondylitis and represents one of the established alternatives to TNF inhibition. COSENTYX is used across several immune-mediated diseases, including ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriatic arthritis, psoriasis, and hidradenitis suppurativa.

COSENTYX generated USD 6.668 billion in global sales during 2025, increasing 9% in reported currency and 8% at constant currency. Novartis specifically reported that growth was supported by volume expansion in core indications that included ankylosing spondylitis and non-radiographic axial spondyloarthritis. COSENTYX generated approximately USD 3.839 billion in the U.S. and USD 2.829 billion outside the U.S. in 2025, demonstrating the global commercial reach of the IL-17 platform.

 

UCB – Dual IL-17A/IL-17F Inhibition

UCB has strengthened its competitive position through BIMZELX (bimekizumab), which uses differentiated dual IL-17A and IL-17F inhibition. Instead of selectively inhibiting IL-17A alone, bimekizumab targets both cytokines involved in inflammatory signaling. In the Phase 3 BE MOBILE 2 ankylosing spondylitis study, 44.8% of bimekizumab-treated patients achieved ASAS40 at Week 16 compared with 22.5% receiving placebo. At Week 52, approximately six in ten bimekizumab-treated patients across the two axial spondyloarthritis studies achieved low disease activity.

Commercial uptake has accelerated rapidly. BIMZELX generated €2.227 billion in 2025 global net sales, compared with €607 million in 2024, and reached more than 116,000 patients. Rheumatology indications comprising psoriatic arthritis, AS, and nr-axSpA collectively represented 19% of 2025 BIMZELX sales. By the first half of 2026, BIMZELX had reached more than 135,000 patients globally and generated €1.528 billion in H1 2026 net sales across its indications.

 

More Biologics Suppliers Extend Ankylosing Spondylitis Treatment Choice

• Eli Lilly and Company — Participates through TALTZ (ixekizumab), an IL-17A antagonist; in biologic-naïve AS patients, 48% achieved ASAS40 at Week 16 versus 18% with placebo in COAST-V.

• Amgen — Maintains an established AS biologic presence through the TNF inhibitor ENBREL (etanercept); ENBREL generated USD 2.226 billion in 2025 sales across its approved indications.

• Johnson & Johnson — Participates through SIMPONI (golimumab), a TNF-targeting monoclonal antibody evaluated for AS in the 356-patient GO-RAISE study, supporting its role in established anti-TNF treatment.

 

Analyst View: Durable Response and Convenient Delivery Shape Treatment Value

The ankylosing spondylitis market is moving from broad inflammation control toward increasingly precise and differentiated disease management. The strongest opportunities are emerging around oral targeted therapies, next-generation cytokine inhibition, dual-pathway biologics, and treatment strategies that provide durable disease control while improving convenience for patients requiring lifelong therapy. JAK inhibitors are expanding the role of oral treatment, while newer IL-17 technologies are increasing competition within advanced biologics. Future value creation will increasingly depend on earlier treatment intervention, stronger long-term response, convenient administration, and the ability to address diverse patient profiles, including those who respond inadequately to established biologics.

 

Ankylosing Spondylitis Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 6.10 Billion
Revenue Forecast in 2032	USD 9.98 Billion
Overall Growth Rate	CAGR of 7.25% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Drug Class / Treatment Type, By Route of Administration, By Distribution Channel, By Geography
By Drug Class / Treatment Type	TNF Inhibitors, IL-17 Inhibitors, NSAIDs, JAK Inhibitors, Conventional DMARDs & Other Treatments
By Route of Administration	Parenteral / Injectable, Oral
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, France, Netherlands, China, India, South Korea, Japan, Brazil, Mexico, UAE, Saudi Arabia, South Africa
Market Drivers	Earlier diagnosis, targeted biologics, oral small-molecule therapies, personalized treatment selection, and technologies capable of controlling specific inflammatory pathways
Customization Option	Available upon request